Table 3.

Mean values (SD) [median values] of biomarkers in women with spontaneous abortions and in control patients

Biomarker
Case patients
Control patients
Difference*
95% confidence interval†
P‡
Anticardiolipin IgG, GPL units   7.7 (12.0) [6.3]   6.2 (4.0) [5.7]   1.4   0.5 to 2.4   < .001  
Anticardiolipin IgM, MPL units   6.7 (3.9) [6.3]   5.8 (3.3) [5.6]   0.9   0.6 to 1.3   < .001  
Anti-phosphatidylethanolamine IgG, × 103  80 (116) [77]   75 (106) [73]   5   −6 to 16   .47  
Anti-phosphatidylethanolamine IgM, × 103  229 (198) [233]   173 (126) [169]   56   40 to 73   < .001  
Anti-β2-glycoprotein I IgG, × 103  108 (98) [113]   92 (56) [90]   16   8 to 24   .001  
Anti-β2-glycoprotein I IgM, × 103  33 (46) [34]   30 (44) [28]   3   −2 to 7   .12  
Anti-annexin V IgG, × 103  153 (125) [158]   123 (68) [124]   30   20 to 40   < .001  
Anti-annexin V IgM, × 103  46 (49) [49]   44 (49) [43]   1   −4 to 7   .26  
Antitissue-type plasminogen activator IgG, × 103  128 (79) [133]   58 (52) [55]   70   64 to 77   < .001  
Antitissue-type plasminogen activator IgM, × 103  49 (50) [48]   47 (49) [47]   2   −3 to 7   .25  
Antitissue factor IgG, × 103  62 (62) [60]   57 (51) [56]   4   −2 to 10   .30  
Antitissue factor IgM, × 103  49 (53) [51]   47 (49) [47]   2   −3 to 8   .32  
Antithrombomodulin IgG, × 103  75 (99) [77]   59 (52) [56]   15   7 to 23   .15  
Antithrombomodulin IgG, × 103  49 (52) [49]   47 (48) [45]   2   −3 to 7   .75  
Homocystein, μM
 		 9.4 (3.2) [6.6]
 		 8.0 (2.3) [7.9]
 		 1.4
 		 1.1 to 1.7
 		 < .001
 
Biomarker
Case patients
Control patients
Difference*
95% confidence interval†
P‡
Anticardiolipin IgG, GPL units   7.7 (12.0) [6.3]   6.2 (4.0) [5.7]   1.4   0.5 to 2.4   < .001  
Anticardiolipin IgM, MPL units   6.7 (3.9) [6.3]   5.8 (3.3) [5.6]   0.9   0.6 to 1.3   < .001  
Anti-phosphatidylethanolamine IgG, × 103  80 (116) [77]   75 (106) [73]   5   −6 to 16   .47  
Anti-phosphatidylethanolamine IgM, × 103  229 (198) [233]   173 (126) [169]   56   40 to 73   < .001  
Anti-β2-glycoprotein I IgG, × 103  108 (98) [113]   92 (56) [90]   16   8 to 24   .001  
Anti-β2-glycoprotein I IgM, × 103  33 (46) [34]   30 (44) [28]   3   −2 to 7   .12  
Anti-annexin V IgG, × 103  153 (125) [158]   123 (68) [124]   30   20 to 40   < .001  
Anti-annexin V IgM, × 103  46 (49) [49]   44 (49) [43]   1   −4 to 7   .26  
Antitissue-type plasminogen activator IgG, × 103  128 (79) [133]   58 (52) [55]   70   64 to 77   < .001  
Antitissue-type plasminogen activator IgM, × 103  49 (50) [48]   47 (49) [47]   2   −3 to 7   .25  
Antitissue factor IgG, × 103  62 (62) [60]   57 (51) [56]   4   −2 to 10   .30  
Antitissue factor IgM, × 103  49 (53) [51]   47 (49) [47]   2   −3 to 8   .32  
Antithrombomodulin IgG, × 103  75 (99) [77]   59 (52) [56]   15   7 to 23   .15  
Antithrombomodulin IgG, × 103  49 (52) [49]   47 (48) [45]   2   −3 to 7   .75  
Homocystein, μM
 		 9.4 (3.2) [6.6]
 		 8.0 (2.3) [7.9]
 		 1.4
 		 1.1 to 1.7
 		 < .001
 

Results of biomarkers with no international unit are given as the calculated slopes of the linear regressions describing the variation of absorbencies during the measurement interval.

*

The difference between corresponding mean values.

†

P based on paired t test.

‡

P based on paired Wilcoxon test.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal